<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Solriamfetol: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Solriamfetol: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Solriamfetol: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="120817" href="/d/html/120817.html" rel="external">see "Solriamfetol: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F53394148"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Sunosi</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F56052989"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Sunosi</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F52914536"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Dopamine and Norepinephrine - Reuptake Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F53073494"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f8711007-1017-4637-a97c-593e06f5423f">Narcolepsy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Narcolepsy:</b> Oral: Initial: 75 mg once daily; may increase based on response and tolerability at an interval of ≥3 days to the maximum dose of 150 mg/day.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9033f88e-182a-4ae6-b4b5-c8a283baf192">Obstructive sleep apnea</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Obstructive sleep apnea:</b> Oral: Initial: 37.5 mg once daily; based on response and tolerability may double the dose at intervals of ≥3 days up to the maximum dose of 150 mg/day.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F53073496"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">eGFR 30 to 59 mL/minute/1.73 m<sup>2</sup>: Initial: 37.5 mg once daily; may increase based on response and tolerability at intervals ≥7 days to the maximum dose of 75 mg/day.</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR 15 to 29 mL/minute/1.73 m<sup>2</sup>: 37.5 mg once daily (maximum: 37.5 mg/day).</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR &lt;15 mL/minute/1.73 m<sup>2</sup>: Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Dialyzable (21%).</p></div>
<div class="block doha drugH1Div" id="F53073497"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment is not likely to be necessary (hepatic metabolism is minimal).</p></div>
<div class="block doe drugH1Div" id="F53073495"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing; consider use of lower doses.</p></div>
<div class="block adr drugH1Div" id="F52922916"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Nervous system: Headache (16%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest discomfort (≤2%), chest pain (&lt;2%), palpitations (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Hyperhidrosis (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased thirst (&lt;2%), weight loss (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (3%), bruxism (&lt;2%), constipation (≤3%), decreased appetite (6% to 9%), diarrhea (4%), nausea (7% to 8%), vomiting (&lt;2%), xerostomia (3% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation (&lt;2%), anxiety (4% to 6%), disturbance in attention (&lt;2%), dizziness (2%), insomnia (5%), irritability (≤3%), jitteriness (≤3%), restlessness (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Tremor (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (&lt;2%), dyspnea (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Cardiovascular: Increased diastolic blood pressure, increased heart rate, increased systolic blood pressure</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Hypersensitivity: Hypersensitivity reaction</p></div>
<div class="block coi drugH1Div" id="F52914493"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Concomitant use with or within 14 days of a monoamine oxidase inhibitor.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to solriamfetol or any component of the formulation; recent myocardial infarction (within 1 year); unstable angina; hypertension (uncontrolled); serious cardia arrhythmias; other serious heart problems; end-stage renal disease.</p></div>
<div class="block war drugH1Div" id="F53073480"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular effects: May cause dose-dependent increases in blood pressure and heart rate. Monitor heart rate and blood pressure prior to and regularly during treatment; control hypertension prior to initiating and during treatment. Avoid use in patients with unstable cardiovascular disease, serious heart arrhythmias, or other serious heart problems. Use caution in patients at high risk for cardiovascular events (eg, patients with known cardiovascular or cerebrovascular disease, preexisting hypertension, advanced age). If increases in blood pressure or heart rate cannot be managed with dose reduction of solriamfetol or other appropriate medical interventions, consider discontinuation of solriamfetol.</p>
<p style="text-indent:-2em;margin-left:4em;">• Psychiatric effects: Psychiatric symptoms including anxiety, insomnia, and irritability have been reported with use. Use cautiously in patients with a history of psychosis or bipolar disorders; solriamfetol has not been studied with these populations. Monitor patients for emergence or exacerbation of psychiatric symptoms; if psychiatric symptoms develop reduce dose or discontinue.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Substance abuse: Solriamfetol may have potential for abuse. Carefully evaluate patients for a recent history of drug abuse, especially stimulant or alcohol abuse, and monitor closely for signs of misuse or abuse.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; dose adjustment required. Patients with moderate or severe renal impairment may be at higher risk of increased blood pressure, heart rate, and psychiatric symptoms due to the prolonged half-life in this population.</p></div>
<div class="block foc drugH1Div" id="F53394149"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sunosi: 75 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sunosi: 150 mg</p></div>
<div class="block geq drugH1Div" id="F53394147"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F53559998"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Sunosi Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mg (per each): $34.89</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $34.89</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F56052990"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sunosi: 75 mg, 150 mg</p></div>
<div class="block csi drugH1Div" id="F53827195"><span class="drugH1">Controlled Substance</span>
<p style="text-indent:0em;display:inline">C-IV</p></div>
<div class="block adm drugH1Div" id="F53073499"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Administer once daily upon awakening. Avoid administration within 9 hours of planned bedtime because of the potential to interfere with sleep.</p></div>
<div class="block meg drugH1Div" id="F53778188"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Sunosi: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F211230s009lbl.pdf%23page%3D23&amp;token=8SrEKQz5TTpY%2B3ltDX2eBVOKZliGNgq0z8Ge015%2FwcPFD5T0zqGK2wVvonK%2BylIfHrtyxDvo%2Fbtq938tKg1ONbNCUyhJI6DmIZLv2Kl0rimhc2WM8SFIoulwGd2AMvge&amp;TOPIC_ID=120816" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211230s009lbl.pdf#page=23</a></p></div>
<div class="block use drugH1Div" id="F52914492"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Narcolepsy or obstructive sleep apnea:</b> To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA).</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Solriamfetol is not indicated to treat the underlying airway obstruction in OSA. Patients should be treated for underlying airway obstruction for at least 1 month prior to and during therapy.</p></div>
<div class="block mst drugH1Div" id="F53073477"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Solriamfetol may be confused with solifFENacin.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F52967568"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OCT2</p></div>
<div class="block dri drugH1Div" id="F52967565"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Anti-Parkinson Agents (Dopamine Agonist): Solriamfetol may enhance the adverse/toxic effect of Anti-Parkinson Agents (Dopamine Agonist). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Stimulants: May enhance the hypertensive effect of Solriamfetol. CNS Stimulants may enhance the tachycardic effect of Solriamfetol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Increasing Effects: Solriamfetol may enhance the hypertensive effect of Herbal Products with Blood Pressure Increasing Effects. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypertension-Associated Agents: Solriamfetol may enhance the hypertensive effect of Hypertension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Solriamfetol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sympathomimetics: May enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F53073478"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse maternal and fetal events were observed in animal reproduction studies.</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to solriamfetol is ongoing. Health care providers are encouraged to enroll patients exposed to solriamfetol during pregnancy in the Sunosi Pregnancy Registry (877-283-6220 or www.SunosiPregnancyRegistry.com). Patients may also enroll themselves.</p></div>
<div class="block brc drugH1Div" id="F53073479"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Data related to the presence of solriamfetol in breast milk are available following a single 150 mg dose administered to 6 healthy lactating patients, 10 days to 52 weeks postpartum. The manufacturer reports the cumulative median concentration of solriamfetol excreted in breast milk over 72 hours was 0.67 mg, or ~5.5% of the weight adjusted maternal dose. The mean elimination half-life of solriamfetol in breast milk was calculated to be ~5 hours, with 78% excreted by 8 hours, and 98% excreted by 24 hours after the maternal dose. The estimated daily infant dose via breast milk was calculated to be 0.112 mg/kg/day providing a relative infant dose (RID) of 5.5% compared to the weight-adjusted maternal dose.</p>
<p style="text-indent:-2em;margin-left:2em;">In general, breastfeeding is considered acceptable when the RID of a medication is &lt;10% (Anderson 2016; Ito 2000). However, some sources note breastfeeding should only be considered if the RID is &lt;5% for psychotropic agents (Larsen 2015).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Exposed infants should be monitored for adverse events such as agitation, anorexia, insomnia, and reduced weight gain.</p></div>
<div class="block mop drugH1Div" id="F53073501"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Blood pressure and heart rate (baseline and regularly during treatment)</p></div>
<div class="block pha drugH1Div" id="F53073483"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">The mechanism of action of solriamfetol is unclear, but its efficacy may be related to its activity as a selective dopamine and norepinephrine reuptake inhibitor (DNRI). Unlike traditional stimulants, it does not promote monoamine release (Baladi 2018).</p></div>
<div class="block phk drugH1Div" id="F53073484"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: ~199 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: Plasma: 13.3% to 19.4%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Minimal</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: ~95%</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~7.1 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 2 hours (fasting); delayed an additional 1 hour with high-fat meal</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (95% as unchanged drug)</p></div>
<div class="block phksp drugH1Div" id="F53073492"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Half-life prolonged 1.2-fold (eGFR 60 to 89 mL/minute/1.73 m<sup>2</sup>), 1.9-fold (eGFR 30 to 59 mL/minute/1.73 m<sup>2</sup>), and 3.9-fold (eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>) in patients with renal impairment. AUC and half-life increased in patients with ESRD. An average of 21% of solriamfetol is removed by hemodialysis.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F56521809"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Sunosi</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Sunosi</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Sunosi</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Sunosi</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Sunosi</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Sunosi</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Sunosi</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Sunosi</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther.</i> 2016;100(1):42-52. doi:10.1002/cpt.377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/solriamfetol-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29891587">
<a name="29891587"></a>Baladi MG, Forster MJ, Gatch MB, et al. Characterization of the neurochemical and behavioral effects of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor. <i>J Pharmacol Exp Ther</i>. 2018;366(2):367-376. doi: 10.1124/jpet.118.248120.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/solriamfetol-drug-information/abstract-text/29891587/pubmed" id="29891587" target="_blank">29891587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>NEJM</i>. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/solriamfetol-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26344706">
<a name="26344706"></a>Larsen ER, Damkier P, Pedersen LH, et al; Danish Psychiatric Society; Danish Society of Obstetrics and Gynecology; Danish Paediatric Society; Danish Society of Clinical Pharmacology. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl.</i> 2015;(445):1-28. doi:10.1111/acps.12479<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/solriamfetol-drug-information/abstract-text/26344706/pubmed" id="26344706" target="_blank">26344706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sunosi.1">
<a name="Sunosi.1"></a>Sunosi (solriamfetol) [prescribing information]. New York, NY: Axsome Therapeutics Inc; June 2023.</div>
</li>
<li>
<div class="reference">
                  Sunosi (solriamfetol) [prescribing information]. Palo Alto, CA: Jazz Pharmaceuticals Inc; October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sunosi.3">
<a name="Sunosi.3"></a>Sunosi (solriamfetol) [product monograph]. Oakville, Ontario, Canada: Innomar Strategies Inc; August 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 120816 Version 74.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
